UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

European journal of cancer (1990), 2017-07, Vol.79, p.50-60

2017

Volltextzugriff (PDF)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

Journal of cancer research and clinical oncology, 2014-09, Vol.140 (9), p.1607-1614

2014

Volltextzugriff (PDF)

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Annals of oncology, 2016-08, Vol.27 (8), p.1565-1572

2016

Volltextzugriff (PDF)

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial)

International journal of cancer, 2016-02, Vol.138 (3), p.739-746

2016

Volltextzugriff (PDF)

The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

Leukemia, 2013-01, Vol.27 (1), p.190-201

2013

Volltextzugriff (PDF)

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

Annals of oncology, 2008-02, Vol.19 (2), p.340-347

2008

Volltextzugriff (PDF)

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

Leukemia, 2012-04, Vol.26 (4), p.830-834

2012

Volltextzugriff (PDF)

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia

Leukemia, 2012-12, Vol.26 (12), p.2549-2552

2012

Volltextzugriff (PDF)

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

British journal of cancer, 2011-07, Vol.105 (2), p.206-211

2011

Volltextzugriff (PDF)

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

Oncology, 2007-01, Vol.73 (5-6), p.407-414

2007

Volltextzugriff (PDF)

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-09, Vol.15 (10), p.1065-1075

2014

Volltextzugriff (PDF)

High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

Oncology, 2005-01, Vol.68 (1), p.71-78

2005

Volltextzugriff (PDF)

Impaired granulocytic function in patients with acute leukaemia : only partial normalisation after successful remission-inducing treatment

Journal of cancer research and clinical oncology, 1998, Vol.124 (2), p.113-116

1998

Volltextzugriff (PDF)

Introducing a standardized assessment of patients’ interest in and usage of CAM in routine cancer care: chances and risks from patients’ and physicians’ point of view

Journal of cancer research and clinical oncology, 2023-12, Vol.149 (18), p.16575-16587

2023

Volltextzugriff (PDF)

Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial

Journal of clinical oncology, 2015-06, Vol.33 (18), p.2028-2034

2015

Volltextzugriff (PDF)

Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study

Clinical genitourinary cancer, 2015-04, Vol.13 (2), p.156-164.e1

2015

Volltextzugriff (PDF)

Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

International journal of cancer, 2021-03, Vol.148 (6), p.1478-1488

2021

Volltextzugriff (PDF)

High Efficacy of Gemcitabine and Cisplatin Plus Trastuzumab in Patients with HER2-overexpressing Metastatic Breast Cancer: A Phase II Study

Clinical oncology (Royal College of Radiologists (Great Britain)), 2005-12, Vol.17 (8), p.630-635

2005

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(18)
Aged
(17)
Female
(17)
Middle Aged
(17)
Adult
(14)
Male
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Chemotherapy
(8)
Treatment Outcome
(8)
Colorectal Neoplasms - Drug Therapy
(7)
Biological And Medical Sciences
(6)
Camptothecin - Analogs & Derivatives
(6)
Cancer Research
(6)
Colorectal Cancer
(6)
Colorectal Neoplasms - Pathology
(6)
Medical Sciences
(6)
Neoplasm Metastasis
(6)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial)

The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

High Efficacy and Low Toxicity of Weekly Docetaxel Given as First-Line Treatment for Metastatic Breast Cancer

Impaired granulocytic function in patients with acute leukaemia : only partial normalisation after successful remission-inducing treatment

Introducing a standardized assessment of patients’ interest in and usage of CAM in routine cancer care: chances and risks from patients’ and physicians’ point of view

Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial

Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study

High Efficacy of Gemcitabine and Cisplatin Plus Trastuzumab in Patients with HER2-overexpressing Metastatic Breast Cancer: A Phase II Study

Aktive Filter

Suchergebnisse filtern